AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
AN2 Therapeutics shares rise 21.05% premarket after announcing GSK collaboration and Gates funding for TB treatment development.
ByAinvest
Monday, Nov 10, 2025 7:28 am ET1min read
AN2 Therapeutics surged 21.05% in premarket trading following the announcement of a collaboration with GSK to develop boron-based LeuRS-inhibitors targeting tuberculosis, supported by a third year of funding from the Gates Foundation. The partnership leverages AN2’s proprietary boron chemistry platform, which the company highlights as a differentiated approach to drug discovery with potential applications in infectious diseases and oncology. Both the collaboration and extended funding signal progress in addressing high-unmet-need therapeutic areas, bolstering investor confidence. The news was reiterated across multiple reports, emphasizing the strategic alliance’s potential to advance TB treatments and validate AN2’s technology. The premarket rally aligns with the perceived value of the partnership and the company’s pipeline advancements, including Phase 1 trials for other indications.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet